Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Viridian Therapeutics, Inc./ 10-K

Annual Report · 10-K

Viridian Therapeutics, Inc.

VRDNNASDAQEQUITYCurrent

Annual Report

Filed Mar 9, 2023Accepted Mar 9, 2023, 7:24 AM ESTCIK 1590750Accession 0001590750-23-000002
View company →Permanent SEC source ↗
Share

Company context

Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes. With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.

Current securities

VRDNNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by Point72 Asset Management, L.P. regarding Viridian Therapeutics, Inc.\DEAug 20, 2026
  2. 144 filingAug 19, 2026
  3. SCHEDULE 13G/A - filed by Kynam Capital Management, LP regarding Viridian Therapeutics, Inc.\DEAug 14, 2026
  4. SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Viridian Therapeutics, Inc.\DEAug 14, 2026
  5. 10-Q filingAug 6, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.